# A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

> **NCT03690388** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Exelixis** · enrollment: 187 (actual)

## Conditions studied

- Differentiated Thyroid Cancer

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03690388
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-10-05
- **Primary completion:** 2020-08-19
- **Final completion:** 2026-07-31
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03690388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03690388, "A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03690388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*